Human papillomaviruses and the specificity of PDZ domain targeting

FEBS Journal

Volumn 279, Issue 19, 2012, Pages 3530-3537

  Pim, David ^a   Bergant, Martina ^a   Boon, Siaw S ^a   Ganti, Ketaki ^a   Kranjec, Christian ^a   Massimi, Paola ^a   Subbaiah, Vanitha K ^a   Thomas, Miranda ^a   Tomaić, Vjekoslav ^a   Banks, Lawrence ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

cancer; cell contact; cell polarity; cell signaling; E6; E6AP; HPV; PDZ; phosphorylation; proteasome

Indexed keywords

CELL MEMBRANE PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 3; PDZ PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN CAL; PROTEIN DLG1; PROTEIN E6; PROTEIN E7; PROTEIN MAGI 1; PROTEIN MAGI 2; PROTEIN MAGI 3; PROTEIN MUPP1; PROTEIN NHERF1; PROTEIN P53; PROTEIN PATJ; PROTEIN SCRIBBLE; PROTEIN TIP 1; PROTEIN TIP 2; UNCLASSIFIED DRUG;

ENZYME SPECIFICITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; VIRUS CARCINOGENESIS; WART VIRUS;

HUMANS; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PDZ DOMAINS; SUBSTRATE SPECIFICITY;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84866412835     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08709.x     Document Type: Review

References (59)

1. zur Hausen H, (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2, 342-350. (Pubitemid 37328947)
2. Parkin DM, Bray F, Ferlay J, &, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108. (Pubitemid 40372904)
3. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al. (2009) A review of human carcinogens. Part B: biological agents. Lancet Oncol 10, 321-322.
4. Smotkin D, &, Wettstein FO, (1986) Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc Natl Acad Sci USA 83, 4680-4684. (Pubitemid 16075465)
5. Androphy EJ, Hubbert NL, Schiller JT, &, Lowy DR, (1987) Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J 6, 989-992.
6. Goodwin EC, &, DiMaio D, (2000) Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dominant tumour suppressor pathways. Proc Natl Acad Sci USA 97, 12513-12518.
7. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, &, Hoppe-Seyler F, (2003) SiRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22, 5938-5945. (Pubitemid 37175872)
8. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, Nishihara T, &, Yamato K, (2003) In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 8, 762-768. (Pubitemid 37527451)
9. Barbosa MS, &, Schlegel R, (1989) The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 4, 1529-1532. (Pubitemid 20008936)
10. Sexton CJ, Proby CM, Banks L, Stables JN, Powell K, Navsaria H, &, Leigh IM, (1993) Characterisation of factors involved in human papillomavirus type 16-mediated immortalisation of oral keratinocytes. J Gen Virol 74, 755-761. (Pubitemid 23113382)
11. Dürst M, Gallahan D, Gilbert J, &, Rhim JS, (1989) Glucocorticoid enhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene. Virology 173, 767-771. (Pubitemid 20014510)
12. Doorbar J, (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 110, 525-541. (Pubitemid 43736116)
13. Wu L, Goodwin EC, Naeger LK, Vigo E, Galaktionov K, Helim K, &, DiMaio D, (2000) E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression. Mol Cell Biol 20, 7059-7067.
14. KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13, 2323-2330.
15. Funk JO, Waga S, Harry JB, Espling E, Stillman B, &, Galloway DA, (1997) Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11, 2090-2100. (Pubitemid 27369103)
16. Ciccolini F, Di Pasquale G, Carlotti F, Crawford L, &, Tommasino M, (1997) Functional studies of E7 proteins from different HPV types. Oncogene 9, 2633-2638.
17. McIntyre MC, Ruesch MN, &, Laimins LA, (1996) Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 215, 73-82. (Pubitemid 26039932)
18. Thomas M, Pim D, &, Banks L, (1999) The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18, 7690-7700. (Pubitemid 30052696)
19. Thomas M, &, Banks L, (1998) Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 17, 2943-2954. (Pubitemid 29012197)
20. Song S, Liem A, Miller J, &, Lambert P, (2000) Human papillomavirus type 16 E6 and E7 contribute differently to carcinogenesis. Virology 267, 141-150. (Pubitemid 30123597)
21. Huh K, Zhou H, Hatakawa H, Cho JY, Libermann TA, Jin J, Harper JW, &, Münger K, (2007) Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumour suppressor. J Virol 81, 9737-9747. (Pubitemid 350067678)
22. Huibregtse J, Scheffner M, &, Howley P, (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10, 4129-4135. (Pubitemid 21905444)
23. Caldeira S, de Villiers EM, &, Tommasino M, (2000) Human papillomavirus E7 proteins stimulate proliferation independently of their ability to associate with retinoblastoma protein. Oncogene 19, 821-826. (Pubitemid 30107713)
24. Lechner MS, &, Laimins LA, (1992) Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 68, 4262-4273.
25. Brimer N, Lyons C, &, Vande Pol S, (2007) Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein. Virology 358, 303-310. (Pubitemid 46136426)
26. Songyang Z, Fanning AS, Fu C, Xu J, Marfatia SM, Chishti AH, Crompton A, Chan AC, Anderson JM, &, Cantley LC, (1997) Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 275, 73-77. (Pubitemid 27020310)
27. Lee SS, Weiss RS, &, Javier RT, (1997) Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci USA 94, 6670-6675.
28. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, &, Ishibashi M, (1997) Binding of high-risk human papillomavirus E6 oncoproteins to a human homologue of the Drosophila discs large tumour suppressor protein. Proc Natl Acad Sci USA 94, 11612-11616. (Pubitemid 27451047)
29. Watson RA, Thomas M, Banks L, &, Roberts S, (2003) Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J Cell Sci 116, 4925-4934. (Pubitemid 38016699)
30. Nguyen ML, Nguyen MM, Lee D, Griep AE, &, Lambert PF, (2003) The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol 77, 6957-6964. (Pubitemid 36666888)
31. Lee C, &, Laimins LA, (2004) Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J Virol 78, 12366-12377. (Pubitemid 39458755)
32. Nakagawa S, &, Huibregtse JM, (2000) Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 20, 8244-8253.
33. Roberts S, Delury C, &, Marsh E, (2012) The PDZ protein human discs large: the 'Jekyll and Hyde' of the epithelial polarity proteins. FEBS J 279, 3549-3558.
34. Facciuto F, Cavatorta AL, Bugnon Valdano M, Marziali F, &, Gardiol D, (2012) Differential expression of PDZ domain-containing proteins in human diseases-challenging topics and novel issues. FEBS J 279, 3538-3548.
35. Kranjec C, &, Banks L, (2011) A systematic analysis of human papillomavirus (HPV) E6 PDZ substrates identifies MAGI-1 as a major target of HPV type 16 (HPV-16) and HPV-18 whose loss accompanies disruption of tight junctions. J Virol 85, 1757-1764.
36. Handa K, Yugawa T, Narisawa-Saito M, Ohno S, Fujita M, &, Kiyono T, (2007) E6AP-dependent degradation of DLG4/PSD95 by high-risk human papillomavirus type 18 E6 protein. J Virol 81, 1379-1389. (Pubitemid 46167859)
37. Favre-Bonvin A, Reynaud C, Kretz-Remy C, &, Jalinot P, (2005) Human papillomavirus type 18 E6 protein binds the cellular PDZ protein TIP-2/GIPC, which is involved in transforming growth factor β signalling, and triggers its degradation by the proteasome. J Virol 79, 4229-4237. (Pubitemid 40388361)
38. Accardi R, Rubino R, Scalise M, Gheit T, Shahzad N, Thomas M, Banks L, Indiveri C, Sylla B, Cardone R, et al. (2011) E6 and E7 from human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1. J Virol 85, 8202-8216.
39. Thomas M, Laura R, Hepner K, Guccione E, Sawyers C, Lasky L, &, Banks L, (2002) Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 21, 5088-5096.
40. Lee SS, Glaunsinger B, Mantovani F, Banks L, &, Javier R, (2000) Multi-PDZ domain protein MUPP is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol 74, 9680-9693.
41. Latorre I, Roh M, Frese K, Weiss R, Margolis B, &, Javier R, (2005) Viral oncoprotein-induced mislocalisation of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells. J Cell Sci 118, 4283-4293. (Pubitemid 41488965)
42. Storrs C, &, Silverstein S, (2007) PATJ, a tight junction-associated PDZ protein, is a novel degradation target of high-risk human papillomavirus E6 and the alternatively spliced isoform 18E6. J Virol 81, 4080-4090. (Pubitemid 46586903)
43. Jing M, Bohl J, Brimer N, Kinter M, &, Vande Pol S, (2007) Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins. J Virol 81, 2231-2239.
44. Töpffer S, Müller-Schiffmann A, Matentzoglu K, Scheffner M, &, Steger G, (2007) Protein tyrosine phosphatase H1 is a target of the E6 oncoprotein of high-risk genital human papillomaviruses. J Gen Virol 88, 2956-2965. (Pubitemid 350131232)
45. Spanos W, Hoover A, Harris G, Wu S, Strand G, Anderson M, Klingelhutz A, Hendriks W, Bossler A, &, Lee J, (2008) The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage- independent growth and synergizes with Ras for invasive growth. J Virol 82, 2493-2500. (Pubitemid 351293550)
46. Jeong KW, Kim HZ, Kim S, Kim YS, &, Choe J, (2007) Human papillomavirus type 16 E6 protein interacts with cystic fibrosis transmembrane regulator-associated ligand and promotes E6-associated protein-mediated ubiquitination and proteasomal degradation. Oncogene 26, 487-499. (Pubitemid 46160963)
47. Hampson L, Li C, Oliver A, Kitchener H, &, Hampson I, (2004) The PDZ protein Tip-1 is a gain-of-function target of the HPV16 E6 oncoprotein. Int J Oncol 25, 1249-1256.
48. Thomas M, Narayan N, Pim D, Tomaić V, Massimi P, Nagasaka K, Kranjec C, Gammoh N, &, Banks L, (2008) Human papillomaviruses, cervical cancer and cell polarity. Oncogene 27, 7018-7030.
49. Subbaiah VK, Kranjec C, Thomas M, &, Banks L, (2011) PDZ domains: the building blocks regulating tumorigenesis. Biochem J 439, 195-205.
50. Thomas M, Massimi P, Navarro C, Borg JP, &, Banks L, (2005) The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins. Oncogene 24, 6222-6230. (Pubitemid 43080045)
51. Zhang Y, Dasgupta J, Ma RZ, Banks L, Thomas M, &, Chen XS, (2007) Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein. J Virol 81, 3618-3626. (Pubitemid 46456670)
52. Zanier K, ould Sidi A, Boulade-Ladame C, Rybin V, Chappelle A, Atkinson A, Kieffer B, &, Travé G, (2012) Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53. Structure 20, 604-617.
53. Matlashewski G, Banks L, Wu-Liao J, Spence P, Pim D, &, Crawford L, (1986) The expression of human papillomavirus type 18 E6 protein in bacteria and the production of anti-E6 antibodies. J Gen Virol 67, 1909-1916. (Pubitemid 16017275)
54. Kühne C, Gardiol D, Guarnaccia C, Amenitsch H, &, Banks L, (2000) Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6. Oncogene 19, 5884-5891. (Pubitemid 32005369)
55. Sabio G, Arthur JS, Kuma Y, Peggie M, Carr J, Murray-Tait V, Centeno F, Goedert M, Morrice NA, &, Cuenda A, (2005) p38γ regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J 24, 1134-1145. (Pubitemid 40516597)
56. Massimi P, Narayan N, Cuenda A, &, Banks L, (2006) Phosphorylation of the discs large tumour suppressor protein controls its membrane localisation and enhances its susceptibility to HPV E6-induced degradation. Oncogene 25, 4276-4285. (Pubitemid 44100498)
57. Qian Y, &, Prehoda KE, (2006) Interdomain interactions in the tumour suppressor discs large regulate binding to the synaptic protein GukHolder. J Biol Chem 281, 35757-35763. (Pubitemid 46041306)
58. Newman RA, &, Prehoda KE, (2009) Intramolecular interactions between SRC homology 3 and guanylate kinase domains of discs large regulate its function in asymmetric cell division. J Biol Chem 284, 12924-12932.
59. Narayan N, Subbaiah VK, &, Banks L, (2009) The high-risk HPV E6 oncoprotein preferentially targets phosphorylated nuclear forms of hDlg. Virology 387, 1-4.